Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis with a silicone-covered nitinol short bilaterally flared stent: a case series

Authors
Raffaele Manta¹, Claudio Zulli², Angelo Zullo³, Edoardo Forti⁴, Alberto Tringali⁴, Lorenzo Dioscoridi⁴, Francesco Zito¹, Helga Bertani¹, Rita Conigliaro¹, Massimiliano Mutignani⁴

Institutions
1 Gastroenterology Unit, Nuovo Ospedale Civile Sant’Agostino-Estense, Baggiovara-Modena, Italy
2 Endoscopy Unit, AOUI San Giovanni di Dio e Ruggi d’Aragona, G. Fucito Center, Mercato San Severino (SA), Italy
3 Gastroenterology Unit, Nuovo Regina Margherita Hospital, Rome, Italy
4 Surgical Endoscopy Unit, ASST Niguarda Hospital, Milan, Italy

submitted 10.5.2017
accepted after revision 24.7.2017

Bibliography
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 2364-3722

Corresponding author
Raffaele Manta, MD, Gastroenterology Unit, Nuovo Ospedale Civile Sant’Agostino-Estense, Viale Giardini Ausl, Baggiovara, Modena, Italy
Fax: +39-059-659235
rafaelemanta4@gmail.com

ABSTRACT
Background and study aim Gallbladder drainage in patients with cholecystitis who are unsuitable for surgery may be performed by endoscopic ultrasound (EUS)-guided placement of specifically designed fully covered metal stents. We describe the first case series of patients treated with a silicone-covered nitinol stent with bilateral anchor flanges.

Patients and methods Data from consecutive patients with acute cholecystitis who were deemed unsuitable candidates for surgery were collected. The stent placement procedure was performed in two tertiary endoscopy centers by four experienced endoscopists. Technical and clinical success rates, as well as adverse events and clinical outcome at follow-up, were assessed.

Results EUS-guided drainage for cholecystitis was performed in 16 patients (mean age 84 years; nine males). Technical and clinical success rates were 100 % (16/16) and 94 % (15/16), respectively; an early failure due to stone impaction occurred in the remaining case and required placement of a new stent. Symptom relief occurred in 11/15 cases (73%) within 1 day, and within 2 days in the remaining 4 patients. Bleeding occurred in two patients (13 %): in one patient intraprocedural bleeding was successfully stopped during endoscopy; and delayed bleeding occurred in one patient requiring arterial embolization for catastrophic bleeding (patient died 10 days later). No cases of cholecystitis recurrence or biliary obstruction were observed during a median follow-up of 112 days (range 49–180 days).

Conclusions Our data showed that EUS-guided gallbladder drainage with a specially designed stent is feasible and successful in patients with acute cholecystitis who are unfit for surgery.

Introduction
Laparoscopic cholecystectomy represents the gold standard treatment for acute cholecystitis in patients without contraindications for early surgery [1]. In very elderly patients, and in those with severe comorbidities or who are unfit for surgery, a conservative approach is generally adopted [2, 3]. In detail, percutaneous transhepatic gallbladder aspiration or drainage, transpapillary endoscopic gallbladder stenting and, more recently, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) have been proposed [4–7]. Unfortunately, the endoscopic transpapillary approach is not always successful, and it is frequently challenging owing to the tortuous anatomy of the cystic duct or the presence of impacted stones [8, 9]. On the other hand, the percutaneous procedure is hampered by a high rate of both adverse events (up to 12 %) and cholecystitis
recurrence, as well as by long-stay hospitalization and catheter-related issues, including psychological aspects [10, 11]. By avoiding an external drainage catheter placement, coupled with a very high success rate, the EUS-GBD method has recently become an attractive alternative for managing acute cholecystitis in high-risk patients who are unfit for surgery [12].

Lumen-apposing metal stents (LAMSs) are novel devices generally used for pancreatic cyst or infectious walled-off pancreatic necrosis drainage [13]. More recently, these devices have also been employed for gallbladder drainage, fixing the gallbladder wall directly to the intestinal lumen, in order to prevent bile leaks and stent migration [14]. However, data on LAMSs for gallbladder drainage are still limited, and the AXIOS vent bile leaks and stent migration [14]. However, data on LAMSs for gallbladder drainage are still limited, and the AXIOS stent (Boston Scientific, Marlborough, Massachusetts) has usually been used for this purpose [15]. Alternatively, a short, fully silicone-covered, nitinol stent that was specifically designed with bilateral anchor flanges (NAGI stent; Taewoong Medical Co., Gyeonggi-do, South Korea), may be used for transluminal drainage [16]. Indeed, such a stent is already employed for pancreatic cyst drainage [17–19], and it has also been successfully used for gallbladder drainage [20]. We report the first case series on placement of the NAGI stent for nonsurgical EUS-GBD in patients with acute cholecystitis who are unfit for surgery.

Patients and methods

Patients

From April 2014 to July 2016, all consecutive patients with acute cholecystitis who were unfit for urgent cholecystectomy after surgical and anesthesiological evaluation were considered for this study. Acute cholecystitis was diagnosed when a patient met the Tokyo guideline criteria for cholecystitis, including a constellation of classic symptoms (right upper quadrant pain, fever, leukocytosis), together with radiological findings (abdominal ultrasound or computed tomography scan) of a thickened gallbladder wall [21]. All of these patients were offered an alternative nonsurgical approach, including percutaneous, transpapillary, or EUS-GBD. Data from those patients accepting the EUS-GBD procedure were systematically collected. Patients gave their informed consent before the endoscopic procedure.

EUS-guided gallbladder drainage

The EUS-GBD procedure was performed in two Italian tertiary endoscopy centers by four experienced endoscopists with a large experience in the management of complex biliary problems (>500 EUS/endoscopic retrograde cholangiopancreatography [ERCP] procedures performed yearly). A linear echoendoscope (GF-UCT180 [Olympus, Tokyo, Japan] or EG-3870 UTK [Pentax, Tokyo, Japan]) was used to identify the gallbladder through the gastric antrum or the duodenal bulb. When feasible, the transduodenal approach was favored. After assessment of local vascular structures with color-flow Doppler, one of the following two approaches was chosen. The gallbladder was punctured with a 19-gauge needle (ECHO-19; Cook Medical, Bloomington, Indiana, USA), and bile aspiration was performed confirming the correct position. Then, a 0.035-inch guidewire (Hydra Jagwire; Boston Scientific) was advanced through the needle and coiled within the gallbladder. Dilatation of the access was achieved with a 10 Fr cystotome (CST-10; Cook Medical). Alternatively, the gallbladder was punctured directly with a 10 Fr cystotome, also achieving access dilatation, and a 0.035-inch guidewire was advanced and coiled into the gallbladder. At the end of the procedure, a fully covered metallic stent, with bilateral anchor flanges (NAGI stent; Taewoong Medical Co.) was placed under fluoroscopic guidance. The NAGI stents used were 20 or 30 mm in length and 12–16 mm in diameter, with flared ends of 20 mm [16].

Outcomes

Technical and clinical success, as well as adverse events and outcome at follow-up, were evaluated. In detail, the technical success was defined as correct stent deployment across the duodenum or the stomach into the gallbladder, as demonstrated by appropriate bile and contrast flow through the stent. Clinical success was defined as resolution of acute cholecystitis symptoms, with regression of biochemistry and radiological alterations. Early and late procedure-related adverse events, and 30-day mortality were recorded. Ward nurses recorded patients’ pain level every day during hospitalization.

Results

A total of 16 patients (mean age 84.8 years, range 49–97 years; nine males) underwent EUS-GBD for gallbladder decompression. Indications for the procedure included calculous cholecystitis (12 cases), acalculous cholecystitis (one case), and biliary obstruction of post-transpillary ERCP biliary stenting (2 pancreatic cancer and 1 cholangiocarcinoma). Transduodenal access was performed in 13 patients (81%), and a transgastric approach was preferred in the remaining 3 patients. The gallbladder was punctured with a 19-gauge needle in 10 patients, and directly with a 10 Fr cystotome in the remaining 6 cases.

Technical and clinical success

As shown in Table 1, EUS-GBD was technically successful in all cases at first attempt (Fig. 1, Fig. 2). However, clinical success was achieved in only 15 patients (94%). In the remaining patient, the clinical failure was due to multiple stones (1.5 cm in diameter) that impacted the NAGI stent lumen early after its successful positioning in the gallbladder. Thus, a double-pigtail plastic stent (10 Fr, 10 cm; Cook Endoscopy) was placed during the same session in order to guarantee the gallbladder drainage. However, the patient experienced cholecystitis recurrence 7 days after the procedure, and was successfully re-treated by placement of a new NAGI stent from the gastric antrum.

Adverse events

Regarding the procedure-related adverse events, mild bleeding from the gastric wall occurred in one patient, and was successfully treated during the same endoscopy session. A 90-year old female with comorbidities experienced massive bleeding from a collateral cystic artery, with severe anemia 15 days following stent placement. After an unsuccessful endoscopic attempt at
hemostasis, radiological embolization was successfully performed. However, the patient died 10 days later from an acute cerebral ischemic attack.

Clinical outcome and follow-up
Among the 15 patients with clinical success, symptoms relief occurred in 11 patients (73 %) within the first day after the procedure, and in the second day in the remaining 4 patients. At follow-up, six additional patients died as a result of myocardial infarction at 2 and 6 months in two cases, acute renal failure after 6 months in one case, pancreatic cancer after 7 months in two cases, and cholangiocarcinoma after 5 months in the remaining case. When excluding the patient described above, no cholecystitis recurrence or biliary obstruction were observed at a median follow-up of 112 days (range 49−180 days). No patient underwent cholecystectomy.

Discussion
The management of patients with acute cholecystitis who are unfit for surgery—such as those who are critically ill or very elderly with advanced American Society of Anesthesiologists score, or those with an inoperable malignancy—is challenging [22, 23]. Nonsurgical approaches include either radiological or endoscopic procedures. Although a similar efficacy between the two approaches has been observed [24], the advantage of EUS-GBD over percutaneous cholecystostomy is fewer adverse events in patients who are unfit for cholecystectomy [25, 26]. Among the endoscopic approaches, the EUS-GBD procedure was first introduced in 2007 [27], and LAMS placement has been the more frequently used procedure in the past years. In detail, the AXIOS stent has been employed, with the advantage of gaining gallbladder drainage without radiological guidance [14, 15]. However, the AXIOS stent is quite costly (3000 euros in Italy). Alternatively, the NAGI stent may be used for transluminal drainage, including pancreatic cyst and cholecystitis [16−20], and the cost of this device is distinctly lower (1000

▶ Table 1 Clinical characteristics and procedure outcomes.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age, years</th>
<th>ASA score</th>
<th>Cause of cholecystitis</th>
<th>Stent feature length, diameter</th>
<th>Technical success</th>
<th>Clinical success</th>
<th>Procedure-related complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>81</td>
<td>III</td>
<td>Biliary stones</td>
<td>2 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>M</td>
<td>88</td>
<td>III</td>
<td>Biliary stones</td>
<td>2 cm; 14 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>F</td>
<td>86</td>
<td>IV</td>
<td>Biliary stones</td>
<td>2 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>F</td>
<td>83</td>
<td>II</td>
<td>Pancreatic mass</td>
<td>2 cm; 14 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>F</td>
<td>88</td>
<td>II</td>
<td>Acalculous</td>
<td>2 cm; 14 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>M</td>
<td>79</td>
<td>II</td>
<td>Biliary stones</td>
<td>2 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>M</td>
<td>91</td>
<td>II</td>
<td>Biliary stones</td>
<td>2 cm; 14 mm</td>
<td>Yes</td>
<td>No</td>
<td>Stent occlusion</td>
</tr>
<tr>
<td>M</td>
<td>87</td>
<td>III</td>
<td>Biliary stones</td>
<td>2 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>F</td>
<td>90</td>
<td>IV</td>
<td>Biliary stones</td>
<td>2 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>Delayed bleeding</td>
</tr>
<tr>
<td>F</td>
<td>94</td>
<td>II</td>
<td>Biliary stones</td>
<td>2 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>F</td>
<td>97</td>
<td>IV</td>
<td>Biliary stones</td>
<td>2 cm; 16 mm</td>
<td>Yes</td>
<td>Not</td>
<td>No</td>
</tr>
<tr>
<td>F</td>
<td>93</td>
<td>II</td>
<td>Biliary stones</td>
<td>3 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>M</td>
<td>77</td>
<td>III</td>
<td>Biliary stones</td>
<td>3 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>M</td>
<td>85</td>
<td>II</td>
<td>Pancreatic mass</td>
<td>3 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>Acute bleeding</td>
</tr>
<tr>
<td>M</td>
<td>49</td>
<td>III</td>
<td>Cholangiocarcinoma</td>
<td>3 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>M</td>
<td>89</td>
<td>III</td>
<td>Biliary stones</td>
<td>3 cm; 16 mm</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

M, male; F, female; ASA, American Society of Anesthesiologists.
euros in Italy) than LAMS (AXIOS or SPAXUS). Although NAGI stent placement requires the use of additional endoscopic devices (19-gauge needle, metallic guidewire, cystotome), the overall cost is lower than 2000 euros, and it further decreases when the gallbladder is directly punctured with the cystotome. Moreover, according to manufacturer labeling, removal of the NAGI stent may be safely performed.

To our knowledge, this is the first large case series of EUS-GBD using NAGI stent placement in patients with calculous or acalculous cholecystitis who are unfit for surgery. Correct stent deployment was technically successful in all patients, with two stents being required in one patient via the duodenal and gastric approaches, respectively. Clinical success was not achieved in one patient (6%) because of early stone impaction. For the remaining cases, the regression of cholecystitis symptoms occurred within 24 hours in two-thirds of cases, and within 2 days in the remaining cases. Our data showed technical and clinical success rates of 100% and 94%, respectively. Of note, these results are comparable to the previous estimates of 91.5% (95% confidence interval [CI] 82.5–96.8) and 90.1% (95%CI 80.7–95.9) for technical and clinical success rates, respectively, when the AXIOS stent was used [14]. Although the NAGI stent exerts a lower lumen-apposing force compared with LAMSs [28], no stent migration occurred in our series. Overall, bleeding occurred in two patients (13%) – one intra-procedural bleed that was successfully stopped during endos-
copy and one delayed bleeding that required arterial embolization. In our case series, the procedure-related mortality was 6% (one patient). Our data are similar to those reported in a previous pooled-data analysis of EUS-GBD procedures, where a 9.9% incidence of procedural adverse events was estimated [14]. This study has some limitations, including the retrospective design, the small number of patients included, and the relatively short follow-up that was due, at least in part, to the overall short survival period, as expected for critically ill patients with a mean age of 85 years.

In conclusion, data from this series showed that EUS-GBD with the NAGI stent is feasible and successful in patients with cholecystitis who are unfit for surgery. When considering its lower cost, NAGI stent placement would appear to be an attractive option in selected patients.

Competing interests

None

References

CORRECTION

Endoscopy International Open 2017; 05: E1111 – E1115
DOI: 10.1055/s-0043-118659

The stent’s diameter was reported in Fr instead of in mm. It was corrected in Table 3 and in the text. This was corrected in the online version on November 29, 2017.